COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021GlobeNewsWire • 11/09/21
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depressionGlobeNewsWire • 11/09/21
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorderGlobeNewsWire • 11/03/21
Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groupsGlobeNewsWire • 10/20/21
COMPASS Pathways to participate in upcoming Maxim and Cantor investor conferencesGlobeNewsWire • 09/21/21
Is the Options Market Predicting a Spike in COMPASS Pathways (CMPS) Stock?Zacks Investment Research • 09/20/21
Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0Benzinga • 09/15/21
COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugsGlobeNewsWire • 09/14/21
COMPASS Pathways to participate in Citi, Morgan Stanley and HC Wainwright investor conferences in SeptemberGlobeNewsWire • 09/07/21
Are Options Traders Betting on a Big Move in COMPASS Pathways (CMPS) Stock?Zacks Investment Research • 08/18/21
COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021GlobeNewsWire • 08/11/21
Growing Psychedelic Interest Will Help Push Compass Pathways Stock Up 3X By 2022InvestorPlace • 08/04/21